Zhaoke Ophthalmology Limited disclosed that it repurchased 1.65 million ordinary shares on the Hong Kong Stock Exchange between 11 June and 30 June 2026. The transactions are pending cancellation, so the company’s issued share count remained unchanged at 548.75 million shares at month-end.

The repurchases were executed in nine tranches at volume-weighted average prices ranging from HKD 2.44 to HKD 2.83 per share. Aggregate consideration is calculated at roughly HKD 4.40 million, implying an overall average cost of about HKD 2.66 per share.

Under the general mandate approved on 15 May 2026, Zhaoke Ophthalmology is authorised to repurchase up to 54.87 million shares. The 1.65 million shares bought to date represent 3.01% of that mandate and approximately 0.30% of the company’s current issued share capital.

A 30-day moratorium on new share issues or treasury-share sales applies until 30 July 2026, in accordance with Hong Kong listing rules.